Atossa Therapeutics, INC. (ATOS) — DEF 14A Filings
All DEF 14A filings from Atossa Therapeutics, INC.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Atossa Seeks Reverse Split to Avoid Nasdaq Delisting
— Dec 22, 2025 Risk: high
Atossa Therapeutics, Inc. (ATOS) is seeking stockholder approval for a reverse stock split at a ratio between 5:1 and 20:1 to address its non-compliance with Na -
Atossa Therapeutics Executive Compensation Details
— Mar 26, 2025 Risk: medium
Atossa Therapeutics, Inc. filed a DEF 14A on March 26, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes -
Atossa Therapeutics Files Definitive Proxy Statement
— May 23, 2024 Risk: medium
Atossa Therapeutics, Inc. filed its definitive proxy statement on May 23, 2024, for its annual meeting of stockholders. The filing outlines the proposals to be
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX